autoimmune diseases
-
Johnson vs. Johnson!
For more reports, please follow DrugTimes
-
【Product for Licensing】Johnson & Johnson just licensed in a STAT6 inhibitor. If you are interested in similar assets, please contact us asap
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
-
Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases
If you are looking for brain-penetrating JAK1/TYK2 inhibitors, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
Orelabrutinib’s revenue hits a new milestone! InnoCare Pharma is fully committed to crafting the second growth curve in autoimmune diseases
Welcome to watch InnoCare Pharma’s 2024 R&D Day!
-
>$600M! Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
-
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
Congratulations to Chimagen and GSK!
-
How effective is Hengrui’s vunakizumab, the first NMPA-approved anti-IL-17A monoclonal antibody developed in China?
Vunakizumab is a self-developed product of Hengrui Pharmaceuticals, being the first domestically developed recombinant anti-IL-17A humanized monoclonal antibody approved in China, and also the first innovative drug launched by Hengrui in the field of autoimmune diseases
-
Morphic’s stock prices soar by 75%! Eli Lilly invests an additional $3.2 billion in the autoimmune field
DrugTimes will present more reports timely. Please stay tuned
